Application notes

Evaluating low volumes formulation performance and benchmarking against mainstream toroidal microfluidic mixers.

Screening RNA-loaded lipid nanoparticles (RNA-LNPs) is vital for developing effective mRNA vaccines and therapeutics. Microfluidic systems, like TAMARA, are revolutionizing this process by minimizing reagent use and providing precise control over nanoparticle characteristics. Our latest study compares TAMARA with toroidal mixers, revealing superior RNA yield, minimal reagent loss, and up to 200% higher protein expression. TAMARA not only optimizes low-volume formulations but also offers scalability and cost-effectiveness, making it a game-changer in RNA-LNP development.

This joint work by Cordouan Technology and Inside Therapeutics presents cutting-edge techniques for formulating and characterizing lipid-based nanoparticles.
The application note introduces how the TAMARA microfluidics platform allows for precise control in liposome production, ensuring optimal size and Polydispersity Index (PDI) control, crucial for drug delivery. Characterization of size and PDI is achieved through the utilization of the VASCO Kin DLS system, which provides real-time monitoring and consistent quality assurance for liposome samples, a key factor for more efficient nanoparticle-based delivery.